Education
About Us
Working with TipRanks
Follow Us
vTv Therapeutics (VTVT)
NASDAQ:VTVT
VTVT Stock Chart & Stats
$37.01
$0.06(0.41%)
At close: 4:00 PM EST
$37.01
$0.06(0.41%)
Day’s Range― - ―
52-Week Range$13.15 - $35.95
Previous CloseN/A
Volume611.00
Average Volume (3M)5.07K
Market Cap
$154.67M
Enterprise Value$72.61M
Total Cash (Recent Filing)$98.50M
Total Debt (Recent Filing)$360.00K
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Feb 19, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding3,938,018
10 Day Avg. Volume5,801
30 Day Avg. Volume5,072
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)6.53
Price to Sales (P/S)78.37
P/FCF Ratio-3.15
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue4.27K
Enterprise Value/Gross Profit-14.52K
Enterprise Value/Ebitda-2.51
Forecast
1Y Price Target
$43.50Price Target Upside17.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StructureThe collaboration structure with M42's IROS is financially advantageous for vTv, as M42 is funding the study while vTv maintains regulatory sponsorship, effectively enabling pipeline advancement with limited use of capital.
Market ExpansionThe geographic focus on Middle Eastern and North African (MENA) markets is strategic given the high prevalence of T2D in the UAE and surrounding countries, creating new potential commercial opportunities for cadi beyond the US/EU.
Regulatory AchievementsThe FDA granted cadisegliatin Breakthrough Therapy Designation, indicating its potential for significant improvement over existing therapies for Type 1 diabetes.
Bears Say
vTv Therapeutics News
VTVT FAQ
What was vTv Therapeutics’s price range in the past 12 months?
vTv Therapeutics lowest stock price was $13.15 and its highest was $35.95 in the past 12 months.
What is vTv Therapeutics’s market cap?
vTv Therapeutics’s market cap is $154.67M.
When is vTv Therapeutics’s upcoming earnings report date?
vTv Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 54 days.
How were vTv Therapeutics’s earnings last quarter?
vTv Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$0.98 by -$0.1.
Is vTv Therapeutics overvalued?
According to Wall Street analysts vTv Therapeutics’s price is currently Undervalued.
Does vTv Therapeutics pay dividends?
vTv Therapeutics does not currently pay dividends.
What is vTv Therapeutics’s EPS estimate?
vTv Therapeutics’s EPS estimate is -1.06.
How many shares outstanding does vTv Therapeutics have?
vTv Therapeutics has 3,938,018 shares outstanding.
What happened to vTv Therapeutics’s price movement after its last earnings report?
vTv Therapeutics reported an EPS of -$1.08 in its last earnings report, missing expectations of -$0.98. Following the earnings report the stock price went up 2.159%.
Which hedge fund is a major shareholder of vTv Therapeutics?
Currently, no hedge funds are holding shares in VTVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
vTv Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.50 (17.54% Upside)
$43.50 (17.54% Upside)
Hedge Fund Trend
Increased
By 51.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.40%
12-Months-Change
Fundamentals
Return on Equity
-54.87%
Trailing 12-Months
Asset Growth
-43.07%
Trailing 12-Months
Company Description
vTv Therapeutics
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
VTVT Stock 12 Month Forecast
Average Price Target
$43.50
▲(17.54% Upside)
Technical Analysis
Ownership Overview
11.52% Insiders
5.85% Mutual Funds
17.67% Other Institutional Investors
63.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---